These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18200803)

  • 1. Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications.
    Cumbie BC; Hermayer KL
    Vasc Health Risk Manag; 2007; 3(6):823-32. PubMed ID: 18200803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative therapeutic principles in the prevention of microvascular and neuropathic complications.
    Gries FA
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S201-7. PubMed ID: 8529515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldose reductase / polyol inhibitors for diabetic retinopathy.
    Obrosova IG; Kador PF
    Curr Pharm Biotechnol; 2011 Mar; 12(3):373-85. PubMed ID: 20939801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of 2-benzoxazolinone derivatives as lead against molecular targets of diabetic complications.
    Vyas B; Choudhary S; Singh PK; Singh B; Bahadur R; Malik AK; Silakari O
    Chem Biol Drug Des; 2018 Dec; 92(6):1981-1987. PubMed ID: 30030901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldose reductase in diabetic microvascular complications.
    Chung SS; Chung SK
    Curr Drug Targets; 2005 Jun; 6(4):475-86. PubMed ID: 16026266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacology of diabetic complications.
    Altan VM
    Curr Med Chem; 2003 Aug; 10(15):1317-27. PubMed ID: 12871132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agents in development for the treatment of diabetic nephropathy.
    Goh SY; Jasik M; Cooper ME
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):447-63. PubMed ID: 18764722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversibility of endothelial dysfunction in diabetes: role of polyphenols.
    Suganya N; Bhakkiyalakshmi E; Sarada DV; Ramkumar KM
    Br J Nutr; 2016 Jul; 116(2):223-46. PubMed ID: 27264638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies.
    Adeshara KA; Diwan AG; Tupe RS
    Curr Drug Targets; 2016; 17(11):1309-28. PubMed ID: 26648059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise?
    Boel E; Selmer J; Flodgaard HJ; Jensen T
    J Diabetes Complications; 1995; 9(2):104-29. PubMed ID: 7599349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the treatment of diabetic retinopathy.
    Wilkinson-Berka JL; Miller AG
    ScientificWorldJournal; 2008 Feb; 8():98-120. PubMed ID: 18264628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products.
    Nakamura N; Obayashi H; Fujii M; Fukui M; Yoshimori K; Ogata M; Hasegawa G; Shigeta H; Kitagawa Y; Yoshikawa T; Kondo M; Ohta M; Nishimura M; Nishinaka T; Nishimura CY
    Free Radic Biol Med; 2000 Jul; 29(1):17-25. PubMed ID: 10962201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H; Munusamy S
    Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of protein kinase C activation in diabetic nephropathy.
    Noh H; King GL
    Kidney Int Suppl; 2007 Aug; (106):S49-53. PubMed ID: 17653211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural products as anti-glycation agents: possible therapeutic potential for diabetic complications.
    Elosta A; Ghous T; Ahmed N
    Curr Diabetes Rev; 2012 Mar; 8(2):92-108. PubMed ID: 22268395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
    Coccheri S
    Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose Reductase: a cause and a potential target for the treatment of diabetic complications.
    Thakur S; Gupta SK; Ali V; Singh P; Verma M
    Arch Pharm Res; 2021 Jul; 44(7):655-667. PubMed ID: 34279787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Advanced Glycation End Products, Sorbitol, and Aldose Reductase by Hydroalcohol Extract of Lagenaria siceraria Mol Standl in Diabetic Complications: An In Vitro Approach.
    Kajal A; Singh R
    J Diet Suppl; 2018 Jul; 15(4):482-498. PubMed ID: 28956665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.